Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma...
July 20 2017 - 8:30AM
Business Wire
- Durable CRs Continued After Recovery of
Normal B Cells
- Anti-CD19 CAR T-cell Therapy Can Be
Curative for Chemorefractory Aggressive NHL
Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy
company, highlighted the recent online publication of results in
Molecular Therapy from a National Cancer Institute (NCI) study of
anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in
patients with aggressive NHL including diffuse large B-cell
lymphoma (DLBCL). The research, led by James N. Kochenderfer, M.D.,
an Investigator in the Experimental Transplantation and Immunology
Branch of the NCI Center for Cancer Research, and Steven A.
Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at NCI's Center
for Cancer Research, was performed pursuant to a Cooperative
Research and Development Agreement (CRADA) between NCI and
Kite.
This work follows previously published data in the February 2015
issue of the Journal of Clinical Oncology in which nine patients
with chemorefractory aggressive NHL were treated with a single dose
of anti-CD19 CAR T cells with a CD28 co-stimulatory domain. Seven
of the 9 patients were evaluable for response. Complete remissions
(CR) were observed in 5 of the 7 evaluable patients. Four of the 5
CRs are ongoing from 38 to 56+ months after treatment. There were
no chronic toxicities attributable to CAR T cells except B-cell
aplasia and hypogammaglobulinemia. Importantly, 3 of 4 patients in
ongoing CR had recovery of normal polyclonal B cells, showing that
durable CRs can be maintained in the absence of continued activity
of anti-CD19 CAR T cells.
“We are encouraged to see durable CRs ongoing for more than 3
years, which raises a possibility of cure, from a single infusion
of anti-CD19 CAR T cells in patients with chemorefractory DLBCL, a
population that previously had no curative treatment options. This
study helps us to understand the long-term potential for this
anti-CD19 CAR T cell therapy (axicabtagene ciloleucel) in the
larger aggressive NHL patient population,” said David Chang, M.D.,
Ph.D., Executive Vice President of Research and Development and
Chief Medical Officer of Kite.
About Kite
Kite is a biopharmaceutical company engaged in the development
of innovative cancer immunotherapies with a goal of providing
rapid, long-term durable response and eliminating the burden of
chronic care. The company is focused on chimeric antigen receptor
(CAR) and T cell receptor (TCR) engineered cell therapies designed
to empower the immune system's ability to recognize and kill
tumors. Kite is based in Santa Monica, CA. For more
information on Kite, please visit www.kitepharma.com. Sign up
to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The press release may, in some
cases, use terms such as "predicts," "believes," "potential,"
"proposed," "continue," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "will," "should" or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking
statements include statements regarding intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: the success of anti-CD19 CAR T-cell therapy.
Various factors may cause differences between Kite's expectations
and actual results as discussed in greater detail in Kite's filings
with the Securities and Exchange Commission, including without
limitation in its Form 10-Q for the quarter ended March 31,
2017. Any forward-looking statements that are made in this press
release speak only as of the date of this press release. Kite
assumes no obligation to update the forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170720005353/en/
KiteChristine CassianoSVP, Corporate Communications &
Investor Relationsccassiano@kitepharma.comorGreg MannVP, Investor
Relationsgmann@kitepharma.com
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Mar 2024 to Apr 2024
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Apr 2023 to Apr 2024